Arcellx, Inc.

Healthcare · Biotechnology · United States

Last price 115.07 USD (Apr 27, 2026, 4:00 PM EDT) · Market cap 6.75B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treatin...